210 results
Page 2 of 11
6-K
EX-99.1
6uhj1njy77uj1tfb
20 Jun 23
Current report (foreign)
5:53pm
6-K
EX-99.1
qzfgmd8bje8kxldt
1 May 23
Current report (foreign)
8:00am
6-K
EX-99.1
t8bmkga
30 Nov 22
Current report (foreign)
9:08pm
6-K
EX-99.2
s07so
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.1
hurg8xs1vm9 x3g56fr6
7 Oct 22
Notice of Annual General Meeting
3:06pm
6-K
EX-99.1
5femspxn3ovluk2v1
14 Sep 22
Current report (foreign)
10:31am
6-K
EX-99.2
vccub feviozx6u4njva
29 Aug 22
Current report (foreign)
4:00pm
424B5
x6d75 1rul
19 Aug 22
Prospectus supplement for primary offering
10:52am
6-K
EX-99.1
a6hiqhrbuowygvdr
1 Aug 22
Current report (foreign)
4:48pm
6-K
duijj9s inbj
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
wbqcd
8 Jul 22
Current report (foreign)
8:58am
6-K
laa9qn4a 95klqew
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
EX-99.2
iohzloggiape x0sjme
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
EX-99.1
mntr mak2bopi1cn
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
EX-99.1
4q5a0het
31 Mar 22
Portage Biotech Provides Update on Clinical-Stage and Development Programs
8:00am